NasdaqGS - Delayed Quote USD

Solid Biosciences Inc. (SLDB)

Compare
6.62 -0.16 (-2.36%)
At close: October 2 at 4:00 PM EDT
6.80 +0.18 (+2.72%)
After hours: October 2 at 4:11 PM EDT
Loading Chart for SLDB
DELL
  • Previous Close 6.78
  • Open 6.77
  • Bid 6.61 x 200
  • Ask 6.66 x 100
  • Day's Range 6.53 - 6.84
  • 52 Week Range 1.81 - 15.05
  • Volume 202,305
  • Avg. Volume 289,974
  • Market Cap (intraday) 255.5M
  • Beta (5Y Monthly) 1.91
  • PE Ratio (TTM) --
  • EPS (TTM) -3.29
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.50

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

www.solidbio.com

88

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SLDB

View More

Performance Overview: SLDB

Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SLDB
7.82%
S&P 500
19.70%

1-Year Return

SLDB
162.70%
S&P 500
33.15%

3-Year Return

SLDB
81.30%
S&P 500
31.04%

5-Year Return

SLDB
95.52%
S&P 500
94.19%

Compare To: SLDB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SLDB

View More

Valuation Measures

Annual
As of 4/4/2024
  • Market Cap

    255.50M

  • Enterprise Value

    90.53M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.32

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    -3.69

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -28.70%

  • Return on Equity (ttm)

    -50.81%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -90.69M

  • Diluted EPS (ttm)

    -3.29

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    190.27M

  • Total Debt/Equity (mrq)

    13.09%

  • Levered Free Cash Flow (ttm)

    -55.01M

Research Analysis: SLDB

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

15.00
18.50 Average
6.62 Current
28.00 High
 

Company Insights: SLDB

People Also Watch